Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke

Completed · Phase 2 · Has a placebo group

Conditions studied: Acute Ischemic Stroke

In brief

The primary objective of the study is to assess the clinical effects of natalizumab versus placebo in acute ischemic stroke on clinical measures of functional independence and activities of daily living. The secondary objective of the study is to explore dose and exposure response and the clinical treatment effects of natalizumab versus placebo in acute ischemic stroke on the following: measures of independence, activities of daily living, neurologic function, quality of life, cognition, and safety and tolerability

Key facts

Study ID
NCT02730455
Run by
Biogen
People needed
277
Starts
2016-07-18
Expected to finish
2017-11-20
Last updated by the study team
2019-01-08

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.